Fig. 6: β3AR agonist and CXCR4 antagonist enhances in vivo bone formation. | npj Regenerative Medicine

Fig. 6: β3AR agonist and CXCR4 antagonist enhances in vivo bone formation.

From: Pharmacological tools to mobilise mesenchymal stromal cells into the blood promote bone formation after surgery

Fig. 6: β3AR agonist and CXCR4 antagonist enhances in vivo bone formation.The alternative text for this image may have been generated using AI.

a–d Rats underwent bilateral posterolateral lumbar fusion surgery followed by rhG-CSF, BRL37344 or vehicle once daily for 4 days. Two hours after the last injection, rats were administered AMD3100 or vehicle. a Representative in vivo NIR fluorescence images of the L4/L5 fusion site at 3 weeks post op. b Representative 3D bone volumes at the L4/L5 fusion site, derived from in vivo µCT scans, at 12 weeks post op. Numerical results of c NIR fluorescence intensity, and d µCT-derived bone volume data. Data represented as individual data points with mean and 95% CI overlaid. n = 8 rats per group; c control vs β3 + AMD3100 aP < 0.01, AMD3100 vs β3 + AMD3100 bP < 0.001; d 6 weeks control vs β3 + AMD3100 aP < 0.05, 12 weeks control/AMD vs β3 + AMD a,bP ≤ 0.001. Twelve weeks control vs rhG-CSF + AMD3100 aP < 0.05 (multiple comparison with Sidak post hoc correction).

Back to article page